Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Authors
Keywords
Cancer, Biomarker, Immunotherapy, Checkpoint inhibitors, Drug resistance, Surmounting drug resistance
Journal
DRUG RESISTANCE UPDATES
Volume 53, Issue -, Pages 100718
Publisher
Elsevier BV
Online
2020-07-15
DOI
10.1016/j.drup.2020.100718
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
- (2020) Qingyang Xiao et al. Journal of Clinical Medicine
- Gasdermin E suppresses tumour growth by activating anti-tumour immunity
- (2020) Zhibin Zhang et al. NATURE
- Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations
- (2020) Monica M. Arroyo et al. Biomolecules
- New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
- (2020) Michele Dal Bo et al. DRUG RESISTANCE UPDATES
- Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
- (2019) Emeric Limagne et al. OncoImmunology
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
- (2019) Ila J Datar et al. CLINICAL CANCER RESEARCH
- YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
- (2019) Emily Hays et al. DRUG RESISTANCE UPDATES
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
- (2019) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
- (2019) Edo Kon et al. DRUG RESISTANCE UPDATES
- Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
- (2019) Hendrik Ungefroren EXPERT OPINION ON THERAPEUTIC TARGETS
- TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma
- (2019) Xiaochen Wang et al. JOURNAL OF HEPATOLOGY
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion
- (2019) Hyungseok Seo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade
- (2019) Rohit R. Jadhav et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The multi-factorial nature of clinical multidrug resistance in cancer
- (2019) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- Wnt signaling and drug resistance in cancer
- (2019) Zheng Zhong et al. MOLECULAR PHARMACOLOGY
- B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
- (2019) Johannes Griss et al. Nature Communications
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
- (2019) Ramy R. Saleh et al. Frontiers in Oncology
- Redundant angiogenic signaling and tumor drug resistance
- (2018) Rajesh N. Gacche et al. DRUG RESISTANCE UPDATES
- Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
- (2018) John Rieth et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- (2018) K. G. Paulson et al. Nature Communications
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
- (2018) Michäel Duruisseaux et al. Lancet Respiratory Medicine
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Modulating ROS to overcome multidrug resistance in cancer
- (2018) Qingbin Cui et al. DRUG RESISTANCE UPDATES
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet
- (2017) P.E. Bunney et al. PHYSIOLOGY & BEHAVIOR
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Microbiome and Anticancer Immunosurveillance
- (2016) Laurence Zitvogel et al. CELL
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
- (2016) Ruud H. Wijdeven et al. DRUG RESISTANCE UPDATES
- Lysosomes as mediators of drug resistance in cancer
- (2016) Benny Zhitomirsky et al. DRUG RESISTANCE UPDATES
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
- (2016) Lucia Festino et al. DRUGS
- Generating long-lived CD8+T-cell memory: Insights from epigenetic programs
- (2016) Pranay Dogra et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Molecular basis of resistance to proteasome inhibitors in hematological malignancies
- (2015) Denise Niewerth et al. DRUG RESISTANCE UPDATES
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
- (2015) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses
- (2014) Rebecca R. Laborde et al. Frontiers in Immunology
- Rationally designed nanovehicles to overcome cancer chemoresistance
- (2013) Yoav D. Livney et al. ADVANCED DRUG DELIVERY REVIEWS
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Targeting the PI3K-AKT-mTOR signaling network in cancer
- (2013) Khurum H. Khan et al. Chinese Journal of Cancer
- Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
- (2012) Nitzan Gonen et al. DRUG RESISTANCE UPDATES
- Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
- (2012) K. N. Kodumudi et al. JOURNAL OF IMMUNOLOGY
- Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
- (2011) Mary L. Disis CANCER IMMUNOLOGY IMMUNOTHERAPY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
- (2011) Alina Shapira et al. DRUG RESISTANCE UPDATES
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now